RT Journal Article SR Electronic T1 An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer JF Cancer Immunology Research JO Cancer Immunol Res FD American Association for Cancer Research SP 365 OP 372 DO 10.1158/2326-6066.CIR-13-0115 VO 1 IS 6 A1 Golden, Encouse B. A1 Demaria, Sandra A1 Schiff, Peter B. A1 Chachoua, Abraham A1 Formenti, Silvia C. YR 2013 UL http://cancerimmunolres.aacrjournals.org/content/1/6/365.abstract AB A posteriori evidence suggests that radiotherapy to a targeted tumor can elicit an immune-mediated abscopal (ab-scopus, away from the target) effect in nontargeted tumors, when combined with an anti-CTL antigen-4 (CTLA-4) monoclonal antibody. Concurrent radiotherapy and CTLA-4 blockade induced immune-mediated abscopal effects in poorly immunogenic preclinical tumor models and patients with metastatic melanoma. However, no such reports exist for patients with metastatic lung adenocarcinoma. We report the first abscopal response in a treatment-refractory lung cancer patient treated with radiotherapy and ipilimumab (a human anti-CTLA-4 monoclonal antibody). A posttreatment increase in tumor-infiltrating cytotoxic lymphocytes, tumor regression, and normalization of tumor markers was observed. One year after treatment with concurrent radiotherapy and ipilimumab, the patient is without evidence of disease. Cancer Immunol Res; 1(6); 365–72. ©2013 AACR.